Previous 10 | Next 10 |
Revance Therapeutics Reports Positive Results from Facial Skin Trial Revance Therapeutics ( RVNC ) reported positive data from its two Phase 2a clinical trials. Both the trials indicated that DaxibotulinumtoxinA or DAXI is efficacious as well as well tolerated. The first study sought to ...
Ipsen ( OTCPK:IPSEY ) will join the Exelixis (NASDAQ: EXEL ) and Roche ( OTCQX:RHHBY ) clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III trials. More news on: Ipsen S.A., Exelixis, Inc., Roche Holding AG, Health...
Exelixis ( EXEL +2.2% ) initiates a Phase 3 clinical trial, CONTACT-02 , evaluating Cabometyx (cabozantinib), combined with Roche's ( OTCQX:RHHBY -1.2% ) Tecentriq (atezolizumab), in patients with metastatic castration-resistant prostate cancer who have received one line of hormonal t...
– Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial – – CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – Exelixis, Inc. (NASDAQ: EXEL) today announce...
Over the past four months, investors have dealt with about a decade's worth of volatility -- and we're not even at the halfway mark of 2020 yet. Uncertainty tied to the coronavirus disease 2019 (COVID-19) pandemic initially sent the broader market screaming to its fastest bear market decline i...
One thing will always catch my eye when looking for biotech companies: product. That might seem obvious at first, because all these companies are clearly working on life-changing or even life-saving therapies. But I can't help favoring those with strong, late-stage pipelines and at least one pro...
Exelixis, Inc. (EXEL) BofA Securities Napa Biopharma Conference Call June 24, 2020 3:30 P.M. ET Company Participants Mike Morrissey - President and Chief Executive Officer Conference Call Participants Jason Gerber - Bank of America Presentation Jason Gerber Good day e...
Exelixis, Inc. (EXEL) BMO Capital Markets Prescription for Success Healthcare Conference June 23, 2020, 16:00 ET Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants George Farmer - BMO Capital Markets Presentation George Fa...
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in a fireside chat as part of the virtual BofA Securities Napa Biopharma Conference on Wednesday, June 24, 2020 at 3:30 PM EDT / 12:30 P...
Viela Bio Wins FDA Approval for Autoimmune Treatment Viela Bio ( VIE ) reported that the FDA has given its nod for Uplizna or inebilizumab-cdon for treating adult patients suffering from neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive. It is estimated that near...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...